Monitoring of haemocoagulative changes during long-term doses of low molecular weight heparin during pregnancy

Česká verzia

Authors: P. Šigutová ¹; Z. Hajšmanová ¹; J. Šlechtová ¹; I. Šubrt ²; L. Hradecký ³; Z. Ulčová-Gallová ³
Authors place of work: Ústav klinické biochemie a hematologie LF UK a FN Plzeň, přednosta prof. MUDr. J. Racek, DrSc., vedoucí pracoviště MUDr. J. Šlechtová ¹; Ústav lékařské genetiky LF UK a FN Plzeň, přednosta MUDr. I. Šubrt ²; Gynekologicko-porodnická klinika LF UK a FN Plzeň, přednosta doc. MUDr. Z. Rokyta, CSc. ³
Published in the journal: Ceska Gynekol 2009; 74(5): 348-354

Summary

Objective:
The aim of study was to compare plasma levels of selected coagulation parameters in pregnant women with long-term administration of low molecular weight heparin (LMWH) versus cohort of healthy women LMWHs untreated.

Design:
Prospective study.

Setting:
Department of Haematology, Institute of Clinical Biochemistry and Haematology, Charles University and University Hospital, Plzen.

Methods:
We examined 67 pregnant women with recurrent fetal loss in previous pregnant history treated by long-term prophylactic administration of LMWH. Blood samples were collected before gestation and at 10th, 20th, 30th gestational weeks.

Results:
Pregnant women with own history of recurrent fetal loss treated by the long-term prophylactic dose of LMWHs during pregnancy have the same values of the coagulation parameters as the control cohort in spite of fact that the clinical efficacy of administered LMWHs is high.

Conclusion:
Our results suggest that heparin may act by many unknown different mechanisms, such as inhibition of complement binding or secretion of prostaglandins.

Key words:
recurrent fetal loss, pregnancy, haemostasis, low molecular weight heparin.

Zdroje

1. Bates, SM., Greer, IA., Hirsch, J., et al. Use of antithrombotic agents during pregnancy. ACCP guidelines, 7th Ed., Chest, 2004, 126, p. 627S-644S.

2. Bates, SM., Greer, IA., Pabinger, I., et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy. ACCP evidence-based clinical practice guidelines. 8th Ed., Chest, 2008, 133, p. 844S-884S.

3. Bick, RL. Recurrent miscarriage syndrome and infertility caused by blood coagulation protein/platelet defects. In: Hematological complications in obstetrics, pregnancy, and gynecology. Ed. Blick, RL., Cambridge University Press, 2006, p. 55-74.

4. Brenner, B. Thrombophilia and pregnancy loss in first intended pregnancy. J Thromb Haemost, 2005, 3, p. 2176–2177.

5. Brenner, B. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications –Yes. J Thromb Haemost, 2003, 1, p. 2070-2072.

6. Brenner, B. Maternal anticoagulant prophylaxis for prevention of pregnancy loss in women with trombophilia. J Thromb Haemost, 2003, 1, p. 416-417.

7. Brenner, B., Hoffman R., Carp H., et al. for the LIVE- ENOX investigators. J Thromb Haemost, 2005, 3, p. 227- 229.

8. Brenner, B. Hemostatic changes in pregnancy. Thrombosis Res, 2004, 114, p. 409-412.

9. De Groot, PD., Derksent RHWM. Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost, 2005, 3, p. 1854–1860.

10. Gris, JC., Mares, P. The long and winding road towards LMWH for pregnancy loss. Thromb Haemost, 2005, 3, p. 224-226.

11. Gris, JC., et al. Low- molecular- weight heparin versus low dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood, 2004, 103, 10, p. 3695-3699.

12. Hajšmanová, Z., Šlechtová, J., Šigutová, P., et al. Průběh těhotenství při dlouhodobém podávání nízkomolekulárního heparinu pro opakované těhotenské ztráty. Čes Gynek, 2008, 73, 5, s. 278-283.

13. Kvasnička, J., Srp, B., Bendl, J., et al. Hemostáza v těhotenství, Čes Gynek, 1994, 59, 1, s. 21-28.

14. Levi, M. All heparins are equal, but some are more equal than others. J Thromb Haemos, 2003, 1, p. 884–885.

15. Lindquist, PG. Low molecular weight heparin for repeated pregnancy loss: is it based on solid evidence? J Thromb Haemost, 2003, 3, p. 221-223.

16. Redline, RW. Hemorrhagic and thrombotic lesions of the placenta, In: Hematological complications in obstetrics, pregnancy, and gynecology. Ed. Blick, RL., Cambridge University Press, 2006, p. 251-268.

17. Rey, E., David, M. Fetal loss, thrombophilia and heparin: the clinician’s dilemma. J Thromb Haemost, 2005, 3, p. 782-783.

18. Walker, D. The use of LMWH in pregnancies at risk: new evidence or perception? J Thromb Haemost, 2005, 3, p. 778-793.

19. Salmon, JE. Are heparins effective in some patiens with recurrent pregnancy loss because they inhibit complement activation? J Thromb Haemost, 2005, 3, p. 783-784.

20. Sudrová, M., Kvasnička, J., Linhartová, P., et al. Trombofilie v těhotenství – fyziologie a patofyziologie hemokoagulačních změn v normální graviditě a při některých patologických těhotenských stavech. Čas Lék čes, 2007, 146, 11, s. 853-857.

21. Ulcova-Gallova, Z., Krauz, V., Novakova, P., et al. Anti- phospholipid antibodies against phosphatidylinositol, and phosphatidylserine are more significant in reproductive failure than antibodies against cardiolipin only. Amer J Reprod Immunol, 54, 2005, p. 112-117.